Measuring the Efficacy of the Coeliac Point of Care Test

Measuring the Efficacy of the Coeliac Point of Care Test

Project Overview

Coeliac Disease (CeD) is a common, life-long chronic inflammatory condition which is highly heritable. It is greatly under-recognised with merely 1 in 5 people in Australia with coeliac disease being diagnosed.   Studies have shown there is often a delay in diagnosis in diagnosis of those presenting with symptoms of coeliac disease of between three and thirteen years.  

Coeliac disease has symptoms which are similar to many other health issues and can be hard to spot. A large number of people with the disease may also not present to their GP as they feel well, but don’t understand they can still be suffering from significant unrecognised harm to their health.

This research project aims to validate the use of a simple test using a pin prick of blood which can provide a quick result as to whether people need to go and have further tests for coeliac disease.  

The Coeliac Point of Care Test

Patients Required

Estimated completion

Sept 2019

Total Patients Required


Study Location

Wesley Medical Research

Project Aim

The overall aim of this study is to compare a new screening and diagnostic method called Point of Care Testing (POCT) to the traditional blood test.

Blood tests have traditionally been collected by drawing 10-15mls from a vein in your arm. POCT is a new technology that provides a rapid and minimally invasive assessment for the presence of coeliac disease-specific antibodies called anti-tTG IgA (Biocard) and DGP IgG (Simtomax).

The tests are simple, the results are available within ten minutes (as opposed to being sent to a laboratory for processing), and require only a finger-prick of blood, which offers unique advantages in patient groups such as children.

Project Impact

If successful, the impact of having this type of quick test available at the GP (at the ‘Point of Care’) means that the GP will have on the spot answers for those at higher risk, and ultimately lead to a faster understanding of whether further testing is required.  GPs will be able to:

  • Quickly screen higher risk patients (first degree relatives of those diagnosed with coeliac disease) without blood tests.
  • Offer patient groups such as children a less traumatic and invasive path to answers
  • Remove the cost and time barriers for screening potentially asymptomatic patients



Dr James Daveson
Gastroenterologist & Lead Researcher

This technology could lead to a simpler, faster diagnosis process – an important step in limiting the damage inflicted by coeliac disease.

James Daveson, Lead Researcher

Our Stories

Wesley Medical Research

Scroll to Top